• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AVTE

    Aerovate Therapeutics Inc.

    Subscribe to $AVTE
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: aerovatetx.com

    Recent Analyst Ratings for Aerovate Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/18/2024$27.00 → $2.00Outperform → In-line
    Evercore ISI
    6/18/2024Buy → Hold
    TD Cowen
    6/18/2024$35.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    6/17/2024Buy → Neutral
    Guggenheim
    6/17/2024Buy → Neutral
    BTIG Research
    6/17/2024$41.00 → $3.00Outperform → Neutral
    Wedbush
    3/25/2024$21.00 → $65.00Buy
    Jefferies
    12/8/2023$35.00Equal Weight
    Wells Fargo
    3/1/2023$36.00Buy
    Guggenheim
    12/6/2022$27.00Neutral → Buy
    BTIG Research
    See more ratings

    Aerovate Therapeutics Inc. SEC Filings

    See more
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

      8-K - Jade Biosciences, Inc. (0001798749) (Filer)

      5/1/25 4:22:23 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.

      SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)

      4/30/25 4:51:40 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/29/25 4:05:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aerovate Therapeutics Inc.

      10-Q - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/25/25 4:30:21 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/23/25 4:37:50 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/21/25 8:07:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Aerovate Therapeutics Inc.

      425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      4/9/25 4:20:40 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Aerovate Therapeutics Inc.

      425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      4/9/25 4:11:31 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/9/25 4:09:42 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Aerovate Therapeutics Inc.

      425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      4/9/25 7:01:27 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aerovate Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fairmount Funds Management Llc

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:16:57 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lavelle Erin

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:15:30 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Klein Lawrence Otto

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:10:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cain Christopher W.

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:07:58 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dobmeier Eric

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:00:21 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Fairmount Funds Management Llc claimed ownership of 3,220,368 shares (SEC Form 3)

      3 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 5:58:01 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Lavelle Erin

      3 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 5:51:34 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Klein Lawrence Otto claimed ownership of 86,215 shares (SEC Form 3)

      3 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 5:44:19 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Cain Christopher W.

      3 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 5:41:29 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Dobmeier Eric

      3 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 5:39:40 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Aerovate Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $1,549,944 worth of shares (928,110 units at $1.67) (SEC Form 4)

      4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)

      6/20/24 5:56:07 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care